EWP
AKRO

Elevation Wealth Partners’s Akero Therapeutics AKRO Stock Holding History

Elevation Wealth Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-202
Closed -$9.59K – 960
2025
Q3 		$9.59K Hold
202
– – ﹤0.01% 392
2025
Q2 		$10.8K Buy
202
+114
+130% +$5.18K ﹤0.01% 364
2025
Q1 		$3.56K Buy
88
+28
+47% +$1.19K ﹤0.01% 423
2024
Q4 		$1.67K Hold
60
– – ﹤0.01% 441
2024
Q3 		$1.72K Hold
60
– – ﹤0.01% 425
2024
Q2 		$1.41K Hold
60
– – ﹤0.01% 460
2024
Q1 		$1.52K Buy
60
+50
+500% +$1.2K ﹤0.01% 422
2023
Q4 		$506 Hold
10
– – ﹤0.01% 413
2023
Q3 		$506 Hold
10
– – ﹤0.01% 311
2023
Q2 		$467 Hold
10
– – ﹤0.01% 324
2023
Q1 		$383 Buy
+10
New +$446 ﹤0.01% 325

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Elevation Wealth Partners's AKRO Position: Q4 2025 in Review

Elevation Wealth Partners sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 202 shares — an estimated $9.59K sold.

Elevation Wealth Partners first reported a position in AKRO in Q1 2023 and held it in 11 quarters. The position peaked at $10.8K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Elevation Wealth Partners reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Elevation Wealth Partners sold 202 Akero Therapeutics shares in Q4 2025, an estimated $9.59K.
  • Elevation Wealth Partners first reported a position in Akero Therapeutics in Q1 2023 and held it in 11 quarters.
  • Elevation Wealth Partners's Akero Therapeutics position peaked at $10.8K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Elevation Wealth Partners's 13F filing for Q4 2025, filed 9 Jan 2026.